Scientists have developed a promising gene therapy approach that significantly improves motor functions and mitigates brain inflammation in mice afflicted with Niemann-Pick type C2 disease. This advancement offers a potential pathway for treating the severe neurological symptoms associated with the disorder.
Innovative Gene Delivery Method
Researchers utilized an adeno-associated virus vector, AAV-BR1, engineered to carry the Npc2 gene. Administered intravenously to six-week-old Npc2-/- mice, the therapy aimed to transduce brain endothelial cells and potentially neurons by crossing the blood-brain barrier. Over a six-week period, the treated mice underwent comprehensive behavioral assessments and post-mortem analyses to evaluate the therapy’s effectiveness.
Significant Therapeutic Outcomes
The treatment yielded remarkable improvements in motor abilities and a notable reduction in neocortical inflammation among the majority of the mice, categorized as high responders. Additionally, the therapy preserved Purkinje cells, essential for motor coordination, and achieved widespread distribution of NPC2 in the brain. This distribution corresponded with decreased cholesterol accumulation in neighboring neurons, which were not directly transduced by the vector. Mass spectrometry imaging further revealed that the therapy partially normalized the altered ganglioside profiles in key brain regions, aligning them closer to healthy controls.
• AAV-BR1-NPC2 vector targets both brain endothelial cells and neurons.
• High responder mice exhibited significant preservation of Purkinje cells.
• Cholesterol levels in neurons decreased where NPC2 was distributed.
• Ganglioside imbalances in the cerebellum and hippocampus were partially corrected.
• The therapy demonstrated potential for cross-correcting gene delivery across the blood-brain barrier.
This study highlights the potential of gene therapy to address complex neurological disorders by effectively delivering therapeutic proteins across the blood-brain barrier. The targeted approach not only alleviates systemic symptoms but also directly combats the neurodegeneration that characterizes Niemann-Pick type C2 disease. Future research will focus on optimizing vector delivery and evaluating long-term efficacy and safety in larger models, paving the way for clinical applications in humans. This breakthrough underscores the transformative impact of genetic interventions in treating previously intractable neurological conditions, offering hope for patients and advancing the field of neurogenetic medicine.

This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.